Selected Bibliography

• Groselj B, Sharma N L, Hamdy F C, Kerr M, and Kiltie A E (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer, 108(4):748-54.

• Qiao Boling, Kerr Martin, Groselj Blaz, Teo Mark TW, Knowles Margaret A, Bristow Robert G, Phillips Roger M, and Kiltie Anne E (2013) Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res, 73(5):1611-20.

• Teo Mark TW, Landi Debora, Taylor Claire F, Elliott Faye, Vaslin Laurence, Cox David G, Hall Janet, Landi Stefano, Bishop D T, and Kiltie Anne E (2012) The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis, 33(3):581-6.

• Choudhury A, Swindell R, Logue J P, Elliott P A, Livsey J E, Wise M, Symonds P, Wylie J P, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke N W, Kiltie A E, and Cowan R A (2011) Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol, 29(733-8).

• Qiao Boling, Ansari Abdul-Haq, Scott Gina B, Sak Sei C, Chambers Philip A, Elliott Faye, Teo Mark TW, Bentley Johanne, Churchman Michael, Hall Janet, Taylor Claire F, Bishop Timothy D, Knowles Margaret A, and Kiltie Anne E (2011) In vitro functional effects of XPC gene rare variants from bladder cancer patients. Carcinogenesis, 32(4):516-21.

Anne Kiltie

The three primary aims of our work are

• To investigate the mechanisms underlying the non-homologous end-joining defective/microhomology-mediated end-joining phenotype seen in muscleinvasive bladder cancer, and to exploit this clinically in combined radiotherapy/biological treatments.
• To investigate expression of the DNA damage signalling protein MRE11 as a potential biomarker for prediction of outcome following radiotherapy and chemotherapy, and to establish the role of other such biomarkers.  This should ultimately allow patient selection for optimal bladder cancer treatment, thus increasing overall cure rates.
• To establish which DNA repair gene germ-line variants implicated in bladder cancer risk would allow identification of high-risk idividuals, who would benefit from prophylactic intervention with targeted screening and lifestyle intervention to minimize bladder cancer mortality.

October 2009 to present    Clinical Group Leader, Gray Institute for Radiation Oncology and Biology, University of Oxford and Honorary Consultant Clinical Oncologist, Oxford Radcliffe NHS Trust.

Nov 2001 - Sept 2009    Senior Lecturer/Honorary Consultant Clinical Oncologist (Radiotherapist), St James's University Hospital and St James's Institute of Oncology, Leeds.

Oct 1999 - Oct 2001    Clinical Research Fellow, ICRF Clare Hall Laboratories, South Mimms, Herts.

Awards, Training and Qualifications

2006   Cancer Research UK Clinician Scientist Fellowship.

1998   ESTRO Varian Radiobiology Research Award.

1999   DM, University of Oxford

1995   FRCR (Clinical Oncology)

1992   MRCP (UK)

1989   MA, Sidney Sussex College, Cambridge University

1988   BM BCh, Oxford University Medical School

1985   BA, Sidney Sussex College, Cambridge University

Table 1 and 2